Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants.

By P. Sieving, R. Caruso, W. Tao, H. Coleman, Darby J. S. Thompson, K. Fullmer, R. Bush. Proceedings of the National Academy of Sciences of the United States of America, 2006

613 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/76e00e62c122d2192e376449a43c26fc9e1a3657

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Świder
2. Cristina L. Mullins
3. M. Peden
4. A. J. Roman
5. Melani B. Olivares
6. R. Calcedo
7. E. Héon
8. J. Pang

Citations in the corpus

• Gene Therapy for Leber Congenital Amaurosis caused by RPE65 mutations: Safety and Efficacy in Fifteen Children and Adults Followed up to Three Years (2011, background): “30-logMAR (3-line) halving of visual angle limit, which is a commonly accepted criterion for clinical significance.(44) It was noted that the second baseline VA was better than the first baseline measurement in 10 study eyes (range, −0.”
• Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial (2008, neutral): “P1 has returned to baseline, using a conventional statistical limit of 3 lines (corresponding to 15 letters) of visual acuity loss or gain as significant (Sieving et al ., 2006).”